WO2024094483A1 - Improved biotechnological process to produce guanidinoacetic acid (gaa) by targeted introduction or by increasing the activity of a transmembrane transport protein belonging to the amino acid-polyamine-organocation superfamily - Google Patents
Improved biotechnological process to produce guanidinoacetic acid (gaa) by targeted introduction or by increasing the activity of a transmembrane transport protein belonging to the amino acid-polyamine-organocation superfamily Download PDFInfo
- Publication number
- WO2024094483A1 WO2024094483A1 PCT/EP2023/079589 EP2023079589W WO2024094483A1 WO 2024094483 A1 WO2024094483 A1 WO 2024094483A1 EP 2023079589 W EP2023079589 W EP 2023079589W WO 2024094483 A1 WO2024094483 A1 WO 2024094483A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- microorganism
- gene
- gaa
- arginine
- creatine
- Prior art date
Links
- BPMFZUMJYQTVII-UHFFFAOYSA-N guanidinoacetic acid Chemical compound NC(=N)NCC(O)=O BPMFZUMJYQTVII-UHFFFAOYSA-N 0.000 title claims abstract description 105
- 230000001965 increasing effect Effects 0.000 title claims abstract description 14
- 230000000694 effects Effects 0.000 title claims abstract description 11
- 108010078791 Carrier Proteins Proteins 0.000 title claims description 15
- 102000014914 Carrier Proteins Human genes 0.000 title claims description 11
- 230000032895 transmembrane transport Effects 0.000 title claims description 11
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 title abstract description 4
- 238000011138 biotechnological process Methods 0.000 title description 2
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 59
- 244000005700 microbiome Species 0.000 claims abstract description 56
- CVSVTCORWBXHQV-UHFFFAOYSA-N creatine Chemical compound NC(=[NH2+])N(C)CC([O-])=O CVSVTCORWBXHQV-UHFFFAOYSA-N 0.000 claims abstract description 38
- 102100040870 Glycine amidinotransferase, mitochondrial Human genes 0.000 claims abstract description 29
- 238000000034 method Methods 0.000 claims abstract description 23
- 229960003624 creatine Drugs 0.000 claims abstract description 19
- 239000006046 creatine Substances 0.000 claims abstract description 19
- 108010073791 Glycine amidinotransferase Proteins 0.000 claims abstract description 16
- 235000018102 proteins Nutrition 0.000 claims abstract description 16
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 16
- 238000012262 fermentative production Methods 0.000 claims abstract description 8
- 241000186226 Corynebacterium glutamicum Species 0.000 claims description 33
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 24
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 claims description 17
- 101150052102 cycA gene Proteins 0.000 claims description 16
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 claims description 14
- 229930064664 L-arginine Natural products 0.000 claims description 14
- 235000014852 L-arginine Nutrition 0.000 claims description 14
- 239000004471 Glycine Substances 0.000 claims description 12
- 150000001413 amino acids Chemical group 0.000 claims description 12
- 101150089004 argR gene Proteins 0.000 claims description 12
- 238000000855 fermentation Methods 0.000 claims description 12
- 230000004151 fermentation Effects 0.000 claims description 12
- 230000002018 overexpression Effects 0.000 claims description 10
- 239000004475 Arginine Substances 0.000 claims description 9
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 9
- 235000009697 arginine Nutrition 0.000 claims description 9
- 102000004190 Enzymes Human genes 0.000 claims description 8
- 108090000790 Enzymes Proteins 0.000 claims description 8
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 claims description 8
- 230000014509 gene expression Effects 0.000 claims description 8
- 229960003104 ornithine Drugs 0.000 claims description 8
- 108010070742 Guanidinoacetate N-Methyltransferase Proteins 0.000 claims description 7
- 102000005756 Guanidinoacetate N-methyltransferase Human genes 0.000 claims description 7
- 108010034634 Repressor Proteins Proteins 0.000 claims description 4
- 102000009661 Repressor Proteins Human genes 0.000 claims description 4
- 108700010070 Codon Usage Proteins 0.000 claims description 3
- 108091081024 Start codon Proteins 0.000 claims description 3
- 230000000051 modifying effect Effects 0.000 claims description 3
- 210000003705 ribosome Anatomy 0.000 claims description 3
- 230000002238 attenuated effect Effects 0.000 claims description 2
- 230000002708 enhancing effect Effects 0.000 claims description 2
- 238000005457 optimization Methods 0.000 claims description 2
- 241000588722 Escherichia Species 0.000 claims 1
- 238000003752 polymerase chain reaction Methods 0.000 description 36
- 108020004414 DNA Proteins 0.000 description 31
- 241000588724 Escherichia coli Species 0.000 description 25
- 210000004027 cell Anatomy 0.000 description 20
- 239000013612 plasmid Substances 0.000 description 20
- 229920001817 Agar Polymers 0.000 description 19
- 239000008272 agar Substances 0.000 description 19
- 238000006243 chemical reaction Methods 0.000 description 18
- 239000002609 medium Substances 0.000 description 17
- 238000004519 manufacturing process Methods 0.000 description 16
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 15
- 238000010367 cloning Methods 0.000 description 14
- 229930027917 kanamycin Natural products 0.000 description 14
- 229960000318 kanamycin Drugs 0.000 description 14
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 14
- 229930182823 kanamycin A Natural products 0.000 description 14
- 230000015572 biosynthetic process Effects 0.000 description 11
- 239000013587 production medium Substances 0.000 description 11
- 101100273648 Mus musculus Ccna2 gene Proteins 0.000 description 9
- RFMMMVDNIPUKGG-YFKPBYRVSA-N N-acetyl-L-glutamic acid Chemical compound CC(=O)N[C@H](C(O)=O)CCC(O)=O RFMMMVDNIPUKGG-YFKPBYRVSA-N 0.000 description 8
- 101100382166 Nitrosomonas europaea (strain ATCC 19718 / CIP 103999 / KCTC 2705 / NBRC 14298) cycA3 gene Proteins 0.000 description 8
- 239000012634 fragment Substances 0.000 description 8
- 239000013615 primer Substances 0.000 description 8
- 101150106538 pscC gene Proteins 0.000 description 8
- 108091008146 restriction endonucleases Proteins 0.000 description 8
- 239000000725 suspension Substances 0.000 description 8
- 241001485655 Corynebacterium glutamicum ATCC 13032 Species 0.000 description 7
- 239000000203 mixture Substances 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- 238000000746 purification Methods 0.000 description 7
- 230000001580 bacterial effect Effects 0.000 description 6
- 238000004520 electroporation Methods 0.000 description 6
- 238000003786 synthesis reaction Methods 0.000 description 6
- 241000894006 Bacteria Species 0.000 description 5
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 5
- 108091028043 Nucleic acid sequence Proteins 0.000 description 5
- 239000008103 glucose Substances 0.000 description 5
- 238000009630 liquid culture Methods 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 101100163308 Clostridium perfringens (strain 13 / Type A) argR1 gene Proteins 0.000 description 4
- 238000007702 DNA assembly Methods 0.000 description 4
- 238000001712 DNA sequencing Methods 0.000 description 4
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 4
- 239000006142 Luria-Bertani Agar Substances 0.000 description 4
- 229930006000 Sucrose Natural products 0.000 description 4
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 4
- 235000013681 dietary sucrose Nutrition 0.000 description 4
- 239000013613 expression plasmid Substances 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 230000003287 optical effect Effects 0.000 description 4
- 229960004793 sucrose Drugs 0.000 description 4
- 230000009466 transformation Effects 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
- QNAYBMKLOCPYGJ-UWTATZPHSA-N D-alanine Chemical compound C[C@@H](N)C(O)=O QNAYBMKLOCPYGJ-UWTATZPHSA-N 0.000 description 3
- RHGKLRLOHDJJDR-BYPYZUCNSA-N L-citrulline Chemical compound NC(=O)NCCC[C@H]([NH3+])C([O-])=O RHGKLRLOHDJJDR-BYPYZUCNSA-N 0.000 description 3
- 108700026244 Open Reading Frames Proteins 0.000 description 3
- 229940041514 candida albicans extract Drugs 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 238000001976 enzyme digestion Methods 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 230000003834 intracellular effect Effects 0.000 description 3
- 230000000813 microbial effect Effects 0.000 description 3
- 108020004707 nucleic acids Proteins 0.000 description 3
- 102000039446 nucleic acids Human genes 0.000 description 3
- 150000007523 nucleic acids Chemical class 0.000 description 3
- 239000000600 sorbitol Substances 0.000 description 3
- 239000007858 starting material Substances 0.000 description 3
- 239000013598 vector Substances 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 239000012138 yeast extract Substances 0.000 description 3
- 244000153158 Ammi visnaga Species 0.000 description 2
- 235000010585 Ammi visnaga Nutrition 0.000 description 2
- KDZOASGQNOPSCU-WDSKDSINSA-N Argininosuccinic acid Chemical compound OC(=O)[C@@H](N)CCC\N=C(/N)N[C@H](C(O)=O)CC(O)=O KDZOASGQNOPSCU-WDSKDSINSA-N 0.000 description 2
- MTCFGRXMJLQNBG-UWTATZPHSA-N D-Serine Chemical compound OC[C@@H](N)C(O)=O MTCFGRXMJLQNBG-UWTATZPHSA-N 0.000 description 2
- 229930195711 D-Serine Natural products 0.000 description 2
- QNAYBMKLOCPYGJ-UHFFFAOYSA-N D-alpha-Ala Natural products CC([NH3+])C([O-])=O QNAYBMKLOCPYGJ-UHFFFAOYSA-N 0.000 description 2
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 2
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 2
- 101100385973 Escherichia coli (strain K12) cycA gene Proteins 0.000 description 2
- 241000644323 Escherichia coli C Species 0.000 description 2
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 2
- 102000003939 Membrane transport proteins Human genes 0.000 description 2
- 108090000301 Membrane transport proteins Proteins 0.000 description 2
- JRLGPAXAGHMNOL-LURJTMIESA-N N(2)-acetyl-L-ornithine Chemical compound CC(=O)N[C@H](C([O-])=O)CCC[NH3+] JRLGPAXAGHMNOL-LURJTMIESA-N 0.000 description 2
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 2
- 108020004511 Recombinant DNA Proteins 0.000 description 2
- 108020005091 Replication Origin Proteins 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- VZTDIZULWFCMLS-UHFFFAOYSA-N ammonium formate Chemical compound [NH4+].[O-]C=O VZTDIZULWFCMLS-UHFFFAOYSA-N 0.000 description 2
- 210000004102 animal cell Anatomy 0.000 description 2
- UCMIRNVEIXFBKS-UHFFFAOYSA-N beta-alanine Chemical compound NCCC(O)=O UCMIRNVEIXFBKS-UHFFFAOYSA-N 0.000 description 2
- 239000007621 bhi medium Substances 0.000 description 2
- 230000006696 biosynthetic metabolic pathway Effects 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 239000006227 byproduct Substances 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 230000002759 chromosomal effect Effects 0.000 description 2
- 229960002173 citrulline Drugs 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 229960002989 glutamic acid Drugs 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 210000005260 human cell Anatomy 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 238000011002 quantification Methods 0.000 description 2
- 238000005215 recombination Methods 0.000 description 2
- 230000006798 recombination Effects 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 238000011144 upstream manufacturing Methods 0.000 description 2
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- 108020003589 5' Untranslated Regions Proteins 0.000 description 1
- 102000037095 APC superfamily Human genes 0.000 description 1
- 108091006314 APC superfamily Proteins 0.000 description 1
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
- QQKKFVXSQXUHPI-NBVRZTHBSA-N Acidissiminol epoxide Chemical compound O1C(C)(C)C1CC(O)C(/C)=C/COC(C=C1)=CC=C1CCNC(=O)C1=CC=CC=C1 QQKKFVXSQXUHPI-NBVRZTHBSA-N 0.000 description 1
- 102000007610 Amino-acid N-acetyltransferase Human genes 0.000 description 1
- 108010032178 Amino-acid N-acetyltransferase Proteins 0.000 description 1
- 241000534414 Anotopterus nikparini Species 0.000 description 1
- 241000203069 Archaea Species 0.000 description 1
- 102000053640 Argininosuccinate synthases Human genes 0.000 description 1
- 108700024106 Argininosuccinate synthases Proteins 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 244000063299 Bacillus subtilis Species 0.000 description 1
- 235000014469 Bacillus subtilis Nutrition 0.000 description 1
- 101100096227 Bacteroides fragilis (strain 638R) argF' gene Proteins 0.000 description 1
- 101710113083 Carbamoyl-phosphate synthase Proteins 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 206010061764 Chromosomal deletion Diseases 0.000 description 1
- 108091035707 Consensus sequence Proteins 0.000 description 1
- 241000186216 Corynebacterium Species 0.000 description 1
- 241001464430 Cyanobacterium Species 0.000 description 1
- 241001299747 Cylindrospermopsis raciborskii Species 0.000 description 1
- DYDCUQKUCUHJBH-UWTATZPHSA-N D-Cycloserine Chemical compound N[C@@H]1CONC1=O DYDCUQKUCUHJBH-UWTATZPHSA-N 0.000 description 1
- DYDCUQKUCUHJBH-UHFFFAOYSA-N D-Cycloserine Natural products NC1CONC1=O DYDCUQKUCUHJBH-UHFFFAOYSA-N 0.000 description 1
- 101710089803 D-serine/D-alanine/glycine transporter Proteins 0.000 description 1
- 238000007399 DNA isolation Methods 0.000 description 1
- 239000003155 DNA primer Substances 0.000 description 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
- 101100342470 Dictyostelium discoideum pkbA gene Proteins 0.000 description 1
- 241000588921 Enterobacteriaceae Species 0.000 description 1
- 241000206602 Eukaryota Species 0.000 description 1
- 108010011689 Glycine transaminase Proteins 0.000 description 1
- 108010025076 Holoenzymes Proteins 0.000 description 1
- 241000282414 Homo sapiens Species 0.000 description 1
- -1 Humm et al. Chemical compound 0.000 description 1
- SNDPXSYFESPGGJ-BYPYZUCNSA-N L-2-aminopentanoic acid Chemical compound CCC[C@H](N)C(O)=O SNDPXSYFESPGGJ-BYPYZUCNSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- 229930182844 L-isoleucine Natural products 0.000 description 1
- SNDPXSYFESPGGJ-UHFFFAOYSA-N L-norVal-OH Natural products CCCC(N)C(O)=O SNDPXSYFESPGGJ-UHFFFAOYSA-N 0.000 description 1
- 239000006137 Luria-Bertani broth Substances 0.000 description 1
- 241001413577 Moorea producens Species 0.000 description 1
- 101100354186 Mycoplasma capricolum subsp. capricolum (strain California kid / ATCC 27343 / NCTC 10154) ptcA gene Proteins 0.000 description 1
- 108010002161 N-acetylornithine deacetylase Proteins 0.000 description 1
- QIMKEDBOQSBFPE-WCCKRBBISA-N NC(=N)NCC(O)=O.NCCC[C@H](N)C(O)=O Chemical compound NC(=N)NCC(O)=O.NCCC[C@H](N)C(O)=O QIMKEDBOQSBFPE-WCCKRBBISA-N 0.000 description 1
- RHGKLRLOHDJJDR-UHFFFAOYSA-N Ndelta-carbamoyl-DL-ornithine Natural products OC(=O)C(N)CCCNC(N)=O RHGKLRLOHDJJDR-UHFFFAOYSA-N 0.000 description 1
- 102000007981 Ornithine carbamoyltransferase Human genes 0.000 description 1
- 101710113020 Ornithine transcarbamylase, mitochondrial Proteins 0.000 description 1
- 239000012807 PCR reagent Substances 0.000 description 1
- 241000589516 Pseudomonas Species 0.000 description 1
- 238000012181 QIAquick gel extraction kit Methods 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- FCHAMFUEENBIDH-UHFFFAOYSA-N Severin Natural products CC1CCC2C(C)C3CCC4(O)C(CC5C4CC(O)C6CC(CCC56C)OC(=O)C)C3CN2C1 FCHAMFUEENBIDH-UHFFFAOYSA-N 0.000 description 1
- 241000187132 Streptomyces kanamyceticus Species 0.000 description 1
- 102000019197 Superoxide Dismutase Human genes 0.000 description 1
- 108010012715 Superoxide dismutase Proteins 0.000 description 1
- 108020005038 Terminator Codon Proteins 0.000 description 1
- 101100323865 Xenopus laevis arg1 gene Proteins 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- 229960003767 alanine Drugs 0.000 description 1
- 229940067621 aminobutyrate Drugs 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 235000019730 animal feed additive Nutrition 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 101150056313 argF gene Proteins 0.000 description 1
- 101150118463 argG gene Proteins 0.000 description 1
- 229940000635 beta-alanine Drugs 0.000 description 1
- 230000036983 biotransformation Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 238000005251 capillar electrophoresis Methods 0.000 description 1
- FFQKYPRQEYGKAF-UHFFFAOYSA-N carbamoyl phosphate Chemical compound NC(=O)OP(O)(O)=O FFQKYPRQEYGKAF-UHFFFAOYSA-N 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- NCEXYHBECQHGNR-UHFFFAOYSA-N chembl421 Chemical compound C1=C(O)C(C(=O)O)=CC(N=NC=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-UHFFFAOYSA-N 0.000 description 1
- 238000013375 chromatographic separation Methods 0.000 description 1
- 235000013477 citrulline Nutrition 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 101150005799 dagA gene Proteins 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- JGBUYEVOKHLFID-UHFFFAOYSA-N gelred Chemical compound [I-].[I-].C=1C(N)=CC=C(C2=CC=C(N)C=C2[N+]=2CCCCCC(=O)NCCCOCCOCCOCCCNC(=O)CCCCC[N+]=3C4=CC(N)=CC=C4C4=CC=C(N)C=C4C=3C=3C=CC=CC=3)C=1C=2C1=CC=CC=C1 JGBUYEVOKHLFID-UHFFFAOYSA-N 0.000 description 1
- 238000002013 hydrophilic interaction chromatography Methods 0.000 description 1
- 238000000126 in silico method Methods 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 238000012269 metabolic engineering Methods 0.000 description 1
- 244000000010 microbial pathogen Species 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 239000013600 plasmid vector Substances 0.000 description 1
- 238000007747 plating Methods 0.000 description 1
- 108091033319 polynucleotide Proteins 0.000 description 1
- 102000040430 polynucleotide Human genes 0.000 description 1
- 239000002157 polynucleotide Substances 0.000 description 1
- 230000001915 proofreading effect Effects 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 238000004064 recycling Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000012807 shake-flask culturing Methods 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 229960004295 valine Drugs 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/1003—Transferases (2.) transferring one-carbon groups (2.1)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/34—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Corynebacterium (G)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/1003—Transferases (2.) transferring one-carbon groups (2.1)
- C12N9/1007—Methyltransferases (general) (2.1.1.)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P13/00—Preparation of nitrogen-containing organic compounds
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P13/00—Preparation of nitrogen-containing organic compounds
- C12P13/04—Alpha- or beta- amino acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y201/00—Transferases transferring one-carbon groups (2.1)
- C12Y201/01—Methyltransferases (2.1.1)
- C12Y201/01002—Guanidinoacetate N-methyltransferase (2.1.1.2)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y201/00—Transferases transferring one-carbon groups (2.1)
- C12Y201/04—Amidinotransferases (2.1.4)
- C12Y201/04001—Glycine amidinotransferase (2.1.4.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
- C12R2001/15—Corynebacterium
Definitions
- GAA guanidinoacetic acid
- GAA Guanidino acetic acid
- W02005120246 A1 and US2011257075 A1 GAA is a natural precursor of creatine (e.g. Humm et al., Biochem. J. (1997) 322, 771-776). Therefore, the supplementation of GAA allows for an optimal supply of creatine in the organism.
- the present invention pertains to a microorganism transformed to be capable of producing guanidinoacetic acid (GAA) and to a method for the fermentative production of GAA using such microorganism.
- GAA guanidinoacetic acid
- the present invention also relates to a method for the fermentative production of creatine.
- GAA and ornithine are formed from arginine and glycine as starting materials by the catalytic action of an L-arginine:glycine-amidinotransferase (AGAT; EC 2.1 .4.1). This reaction is also the first step in creatine biosynthesis.
- Fan Wenchao discloses a method for the production of creatine by fermentation of non-pathogenic microorganisms, such as Corynebacterium glutamicum (CN106065411 A).
- the microorganism has the following biotransformation functions: glucose conversion to L-glutamic acid; conversion of L- glutamic acid to N-acetyl-L-glutamic acid; conversion of N-acetyl-L-glutamic acid to N-acetyl-L- glutamic acid semialdehyde; conversion of N-acetyl-L-glutamic acid semialdehyde to N- acetyl-L- ornithine; conversion of N-acetyl-L-ornithine to L-ornithine; conversion of L-ornithine to L-citru Hine; conversion of L-citrulline to arginino-succinic acid; conversion of arginino-succinic acid to L- arginine
- the microorganism overexpresses one or more enzymes selected from the group consisting of N-acetylglutamate-synthase, N- acetylornithine-6-aminotransferase, N-acetylornithinase, ornithine-carbamoyl transferase, argininosuccinate synthetase, glycine amidino-transferase (EC: 2.1. 4.1), and guanidinoacetate N- methyltransferase (EC: 2.1 .1 .2).
- the microorganism overexpresses preferably glycine aminotransferase (L-arginine:glycine amidinotransferase) and guanidinoacetate N- methyltransferase.
- a microorganism capable of producing guanidinoacetic acid (GAA) was published by Zhang et al. (ACS Synth. Biol. 2020, 9, 2066-275). They designed a reconstituted the ornithine cycle in E. coli by introducing a heterologous AGAT from different species (e.g., Homo sapiens, Cylindrospermopsis raciborskii, Moorea producens) and by introducing a citrulline synthesis module (e.g. ovexpression of argF and argl) and an arginine synthesis module (e.g. overexpression of argG, argH introduction of aspA) into E. coli.
- a heterologous AGAT from different species
- a citrulline synthesis module e.g. ovexpression of argF and argl
- an arginine synthesis module e.g. overexpression of argG, argH introduction of aspA
- WO2021122400 A1 propose a method to produce GAA using a microorganism having a gene coding for a protein having the function of an L-arginine:glycine amidinotransferase (AGAT) and an increased carbamoyl phosphate synthase.
- AGAT L-arginine:glycine amidinotransferase
- carbamoyl phosphate is an important precursor for the biosynthesis of GAA but also for L-arginine and other compounds.
- Ginesy et al. (Microbial Cell Factories (2015) 14:29) report the successful engineering of E. coli for enhanced arginine production. Among other, they proposed the deletion of the argR repressor gene.
- CycA from E. coli has been characterized as a secondary, H + dependent uptake transporter for D- alanine, D-serine, glycine, L-alanine, D-cycloserine (Robbins73, Cosloy73) and beta-alanine (Schneider et al., Appl Microbiol Biotechnol. 2004 Oct;65(5):576-82. doi: 10.1007/s00253-004- 1636-0. Epub 2004 Jun 24. PMID: 15221223). Also, Pulvermacher et al.
- the CycA protein has not been biochemically characterized yet and accordingly, its function in C. glutamicum is unknown.
- the problem underlying the present inventions is to provide a microorganism transformed to be capable for producing guanidinoacetic acid (GAA) in higher amounts and a method for producing GAA using such microorganism.
- GAA guanidinoacetic acid
- a microorganism comprising at least one heterologous gene coding for a protein having the function of a L-arginine:glycine amidinotransferase (AGAT, e.g. EC2.1.4.1) and having an overexpressed gene coding for a transmembrane transport protein with an amino acid sequence having at least 50 % identity to the sequence according to SEQ ID NO: 4.
- the amino acid sequence of the transmembrane transport protein may be at least 50 %, 66 %, 70 %, 80 % or 90 % identical to the sequence according to SEQ ID NO: 4.
- the amino acid sequence of the transmembrane transport protein is at least 66 % identical, more preferably identical to the sequence according to SEQ ID NO: 4.
- SEQ ID NO:3 shows the nucleotide sequence of the respective cycA gene.
- SEQ ID NO:4 is the amino acid sequence of the CycA protein of C. glutamicum.
- the CycA protein of C. glutamicum is a transmembrane transport protein belonging to the Amino Acid-Polyamine-Organocation Superfamily (TC 2. A.3) of transporters (Saier MH, Reddy VS, Moreno-Hagelsieb G, Hendargo KJ, Zhang Y, Iddamsetty V, Lam KJK, Tian N, Russum S, Wang J, Medrano-Soto A. “The Transporter Classification Database (TCDB): 2021 update.” Nucleic Acids Res. 2021 Jan 8;49(D1):D461-D467. doi: 10.1093/nar/gkaa1004).
- TCDB Transporter Classification Database
- a microorganism in the context of the present invention is an organism of microscopic size, which may exist in its single-celled form or as a colony of cells.
- Microorganisms include most unicellular organisms from all three domains of life. The domains Archaea and Bacteria contain microorganisms only. Among the third domain Eukaryota unicellular organism like yeasts, protists and protozoans belong to the group of microorganisms. Multicellular organisms or parts of them, like cell cultures, in particular cultures of animal cells, e.g. of human cells, are not considered as microorganism in the context of the present invention. Animal cells, e.g. human cells, are explicitly excluded from the definition of microorganisms in the context of the present invention.
- the microorganism according to the present invention is capable to produce GAA in higher amounts without the addition of glycine to the production medium
- a heterologous gene means that the gene has been inserted into a host organism which does not naturally have this gene. Insertion of the heterologous gene in the host is performed by recombinant DNA technology. Microorganisms that have undergone recombinant DNA technology are called transgenic, genetically modified or recombinant.
- a heterologous protein means a protein that is not naturally occurring in the microorganism.
- a homologous or endogenous gene means that the gene including its function as such or the nucleotide sequence of the gene is naturally occurring in the microorganism or is “native” in the microorganism.
- a homologous or a native protein means a protein that is naturally occurring in the microorganism.
- the activity of the protein having the function of an L-arginine:glycine amidinotransferase is preferably increased compared to the respective activity in the wildtype organism.
- the AGAT activity is increased by overexpression of the gene coding for the protein having the function of an L-arginine:glycine amidinotransferase.
- the protein having the function of an L- arginine:glycine amidinotransferase comprises an amino acid sequence which is at least 80 % homologous to the amino acid sequence according to SEQ ID NO:2.
- Overexpression of a gene is generally achieved by increasing the copy number of the gene and/or by functionally linking the gene with a strong promoter and/or by enhancing the ribosomal binding site and/or by codon usage optimization of the start codon or of the whole gene and/or by modifying activities of proteins modulating gene expression or a combination comprising a selection of all methods mentioned above.
- a promoter is a DNA sequence consisting of about 40 to 50 base pairs and which constitutes the binding site for an RNA polymerase holoenzyme and the transcriptional start point, whereby the strength of expression of the controlled polynucleotide or gene can be influenced.
- strong promoters for example by replacing the original promoter with strong, native (originally assigned to other genes) promoters or by modifying certain regions of a given, native promoter (for example its so-called -10 and -35 regions) towards a consensus sequence, e.g. as taught by M. Patek et al. (Microbial Biotechnology 6 (2013), 103-117) for C. glutamicum.
- a “strong” promoter is the superoxide dismutase (sod) promoter (“Psod”; Z. Wang et al., Eng. Life Sci. 2015, 15, 73-82).
- a “functional linkage” is understood to mean the sequential arrangement of a promoter with a gene, which leads to a transcription of the gene.
- the microorganism according to the present invention may have an increased ability to produce L- arginine from L-ornithine compared with the ability of the wildtype microorganism.
- a microorganism having an increased ability to produce L- arginine means a microorganism producing L-arginine in excess of its own need.
- L-arginine producing bacteria are e.g. C. glutamicum ATCC 21831 orthose disclosed by Park et al. (NATURE COMMUNICATIONS
- L-arginine excretion is not necessary in strains for GAA production since arginine is utilized inside the cell in the framework of the present invention for GAA production.
- the expression of an argR gene coding for the arginine responsive repressor protein ArgR is attenuated compared to the expression of the argR gene in the wildtype microorganism.
- the argR gene is deleted.
- the microorganism of the present invention may belong to the genus Corynebacterium, to the genus Bacillus (Yan, K., et al. (2022). "Biosynthesis of Guanidinoacetate by Bacillus subtilis Whole- Cell Catalysis.” Fermentation 8(3):116), to the genus Enterobacteriaceae or to the genus Pseudomonas.
- the microorganism is Corynebacterium glutamicum (C. glutamicum) or Escherichia coli (E. coli).
- the present invention further concerns a method for the fermentative production of guanidino acetic acid (GAA), comprising the steps of cultivating the microorganism according to the present invention in a medium, and accumulating GAA in the medium to form a GAA containing fermentation broth.
- GAA guanidino acetic acid
- the method according to the present invention may be further characterized in that no glycine is added to the medium.
- the method further comprises isolating GAA from the GAA containing fermentation broth.
- the microorganism of the present invention further comprises a gene coding for an enzyme having the activity of a guanidinoacetate N-methyltransferase.
- the gene coding for an enzyme having the activity of a guanidinoacetate N-methyltransferase may be overexpressed.
- the present invention also concerns a method for the fermentative production of creatine, comprising the steps of a) cultivating the microorganism according to the present invention further comprising a gene coding for an enzyme having the activity of a guanidinoacetate N- methyltransferase in a suitable medium under suitable conditions, and b) accumulating creatine in the medium to form a creatine containing fermentation broth.
- the method further comprises isolating creatine from the creatine containing fermentation broth.
- Creatine may be extracted from fermentation broth by isoelectric point method and I or ion exchange method.
- creatine can be further purified by a method of recrystallization in water.
- SEQ ID NO:1 Open reading frame coding for a L-arginine:glycine amidinotransferase (AGAT_Mp, EC 2.1 .4.1 ; locus_tag BJP34_00300) of Moorena producens.
- SEQ ID NO:2 The derived AGAT_Mp amino acid sequence (Genbank accession Number WP_070390602)
- SEQ ID NO:5 AGAT-Mp insert ordered for gene synthesis
- SEQ ID NO:6 E. coli-C. glutamicum shuttle plasmid pLIB_P
- SEQ ID NO:7 PCR primer cycA_f_Notl
- SEQ ID NO:8 PCR primer cycA_r_Notl
- SEQ ID NO:9 PCR primer DargRJf
- SEQ ID NQ:10 PCR primer DargRJr
- SEQ ID NO:11 PCR primer DargR_rf
- SEQ ID NO:12 PCR primer DargR_rr
- Kanamycin solution from Streptomyces kanamyceticus was purchased from Sigma Aldrich (St. Louis, USA, Cat. no. K0254). If not stated otherwise, all other chemicals were purchased analytically pure from Merck (Darmstadt, Germany), Sigma Aldrich (St. Louis, USA) or Carl-Roth (Karlsruhe, Germany).
- cultivation I incubation procedures were performed as follows herewith: a. LB broth (MILLER) from Merck (Darmstadt, Germany; Cat. no. 110285) was used to cultivate E. coli strains in liquid medium. The liquid cultures (10 ml liquid medium per 100 ml Erlenmeyer flask with 3 baffles) were incubated in the Infors HT Multitron standard incubator shaker from Infors GmbH (Bottmingen, Switzerland) at 30°C and 200 rpm. b. LB agar (MILLER) from Merck (Darmstadt, Germany, Cat. no. 110283) was used for cultivation of E. coli strains on agar plates.
- MILLER LB broth
- agar plates were incubated at 30°C in an INCU- Line® mini incubator from VWR (Radnor, USA).
- BHI Brain heart infusion broth
- the liquid cultures (10 ml liquid medium per 100 ml Erlenmeyer flask with 3 baffles) were incubated in the Infors HT Multitron standard incubator shaker from Infors GmbH (Bottmingen, Switzerland) at 30°C and 200 rpm.
- BHI-agar Brain heart agar (BHI-agar) from Merck (Darmstadt, Germany, Cat. no. 113825) was used for cultivation of C.
- optical density of bacterial suspensions a. The optical density of bacterial suspensions in shake flask cultures was determined at 600 nm (OD600) using the Bio-Photometer from Eppendorf AG (Hamburg, Germany). b. The optical density of bacterial suspensions produced in the Wouter Duetz (WDS) micro fermentation system (24-Well Plates) was determined at 660 nm (OD660) with the GENiosTM plate reader from Tecan Group AG (Mannedorf, Switzerland).
- Plasmid DNA was isolated from E. coli cells using the QIAprep Spin Miniprep Kit from Qiagen (Hilden, Germany, Cat. No. 27106) according to the instructions of the manufacturer.
- PCR with a proof reading (high fidelity) polymerase was used to amplify a desired segment of DNA for sequencing or DNA assembly.
- Non-proof-reading polymerase Kits were used for determining the presence or absence of a desired DNA fragment directly from E. coli or C. glutamicum colonies.
- the Phusion® High-Fidelity DNA Polymerase Kit (Phusion Kit) from New England BioLabs Inc. (Ipswich, USA, Cat. No. M0530) was used for template-correct amplification of selected DNA regions according to the instructions of the manufacturer (see Table 1).
- Table 1 Thermocycling conditions for PCR with Phusion® High-Fidelity DNA Polymerase Kit from New England BioLabs Inc. b. Taq PCR Core Kit (Taq Kit) from Qiagen (Hilden, Germany, Cat. No.201203) was used to amplify a desired segment of DNA to confirm its presence. The kit was used according to the instructions of the manufacturer (see Table 2).
- Table 2 Thermocycling conditions for PCR with Taq PCR Core Kit (Taq Kit) from Qiagen.
- Table 3 Thermocycling conditions for PCR with SapphireAmp® Fast PCR Master Mix (Sapphire Mix) from Takara Bio Inc. d. All oligonucleotide primers were synthesized by Eurofins Genomics GmbH (Ebersberg, Germany). e.
- PCR template either a suitably diluted solution of isolated plasmid DNA or of total DNA isolated from a liquid culture or the total DNA contained in a bacterial colony (colony PCR) was used.
- colony PCR the template was prepared by taking cell material with a sterile toothpick from a colony on an agar plate and placing the cell material directly into the PCR reaction tube. The cell material was heated for 10 sec.
- DNA fragments a. The sizes of small DNA fragments ( ⁇ 1000 bps) were usually determined by automatic capillary electrophoresis using the QIAxcel from Qiagen (Hilden, Germany). b. If DNA fragments needed to be isolated or if the DNA fragments were >1000 bps DNA was separated by TAE agarose gel electrophoresis and stained with GelRed® Nucleic Acid Gel Stain (Biotium, Inc., Fremont, Canada). Stained DNA was visualized at 302 nm.
- PCR amplificates and restriction fragments were cleaned up using the QIAquick PCR Purification Kit from Qiagen (Hilden, Germany; Cat. No. 28106), according to the manufacturer’s instructions. DNA was eluted with 30 pl 10 mM TrisTICI (pH 8.5).
- DNA concentration was measured using the NanoDrop Spectrophotometer ND-1000 from PEQLAB Biotechnologie GmbH, since 2015 VWR brand (Er Weg, Germany).
- Plasmid vectors were assembled using the “NEBuilder HiFi DNA Assembly Cloning Kit” purchased from New England BioLabs Inc. (Ipswich, USA, Cat. No. E5520). The reaction mix, containing the linear vector and at least one DNA insert, was incubated at 50°C for 60 min. 0.5 pl of Assembly mixture was used for each transformation experiment.
- Transformation of C. glutamicum with plasmid-DNA was conducted via electroporation using a focusedGene Pulser Xcell" (Bio-Rad Laboratories GmbH, Feldmün, Germany) as described by Ruan et al. (2015). Electroporation was performed in 1 mm electroporation cuvettes (Bio-Rad Laboratories GmbH, Feldmün, Germany) at 1 .8 kV and a fixed time constant set to 5 ms. Transformed cells were selected on BHI-agar containing 134 g/l sorbitol, 2.5 g/l Yeast Extract and 25 mg/l kanamycin.
- C. glutamicum strains Corynebacterium glutamicum ATCC13032 (DSM 20300, Kinoshita S, Udaka S, Shimono M., J. Gen. Appl. Microbiol. 1957; 3(3): 193-205), the C. glutamicum m ⁇ d type strain, is commercially available at the American Type Culture Collection (ATCC) or at the DSMZ-German Collection of Microorganisms and Cell Cultures GmbH.
- ATCC American Type Culture Collection
- DSMZ-German Collection of Microorganisms and Cell Cultures GmbH DSMZ-German Collection of Microorganisms and Cell Cultures GmbH.
- Nucleotide sequences of DNA molecules were determined by Eurofins Genomics GmbH (Ebersberg, Germany) by cycle sequencing, using the dideoxy chain termination method of Sanger et al. (Proceedings of the National Academy of Sciences USA 74, 5463 - 5467, 1977).
- E. coli- and C. glutamicum strains For long time storage of E. coli- and C. glutamicum strains glycerol stocks were prepared. Selected E. coli clones were cultivated in 10 ml LB medium supplemented with 2 g/l glucose. Selected C. glutamicum clones were cultivated in 10 ml twofold concentrated BHI medium supplemented with 2 g/l glucose. Media for growing plasmid containing E. coli- and C. glutamicum strains were supplemented with 25 mg/l kanamycin. The medium was contained in 100 ml Erlenmeyer flasks with 3 baffles. It was inoculated with a loop of cells taken from a colony.
- the culture was then incubated for 18 h at 30°C and 200 rpm. After said incubation period 1.2 ml 85 % (v/v) sterile glycerol were added to the culture. The obtained glycerol containing cell suspension was then aliquoted in 2 ml portions and stored at -80°C.
- SM seed medium
- the medium was contained in a 100 ml Erlenmeyer flask with 3 baffles. It was inoculated with 100 pl of a glycerol stock culture and the culture was incubated for 24 h at 30°C and 200 rpm.
- the composition of the seed medium (SM) is shown in Table 4.
- the optical densities OD600 of the precultures were determined.
- the main cultures were started by inoculating the 2.4 ml production medium (PM) containing wells of the 24 Well WDS-Plate with each 100 pl of the resuspended cells from the precultures.
- the composition of the production medium (PM) is shown in Table 5.
- the main cultures were incubated for 72 h at 30 °C and 225 rpm in an Infors HT Multitron standard incubator shaker from Infors GmbH (Bottmingen, Switzerland) until complete consumption of glucose.
- the glucose concentration in the suspension was analyzed with the blood glucose-meter OneTouch Vita® from LifeScan (Johnson & Johnson Medical GmbH, Neuss, Germany).
- the culture suspensions were transferred to a deep well microplate. A part of the culture suspension was suitably diluted to measure the GD600. Another part of the culture was centrifuged and the concentration of GAA in the supernatant was analyzed as described below.
- the HPLC system was started with 100 % B, followed by a linear gradient for 22 min and a constant flow rate of 0,6 mL/min to 66 % B.
- the mass analyzer was operated in the ESI positive ionization mode.
- For detection of GAA the m/z values were monitored by using an MRM fragmentation [M+H] + 118 - 76.
- the limit of quantification (LOQ) for GAA was fixed to 7 ppm.
- Example 1 Cloning of the gene AGAT-Mp coding for an L-arginine:glycine amidinotransferase (AGAT, EC 2.1 .4.1) from Moorena producens
- Moorena producens is a filamentous cyanobacterium.
- the genome of the Moorena producens strain PAL-8-15-08-1 was published by Leao et al. (Leao T, Castelao G, Korobeynikov A, Monroe EA, Podell S, Glukhov E, Allen EE, Gerwick WH, Gerwick L, Proc Natl Acad Sci U S A. 2017 Mar 21 ;114(12):3198-3203. doi: 10.1073/pnas.16185561 14; Genbank accession Number CP017599.1).
- SEQ ID NO:2 shows the derived amino acid sequence (Genbank accession Number WP_070390602).
- AGAT-Mp- insert SEQ ID NO:5
- pEX-A258_AGAT-Mp an ampicillin resistance gene
- the E. coli-C. glutamicum shuttle plasmid pLIB_P consists of the replication origin from pBL1 (for C. glutamicum), the pSC101 replication origin (for E. coli) and a kanamycin resistance gene. Following a unique Not restriction site it has a strong promoter, two inversely orientated Bsal-sites and the BioBricks Terminator BBa_B1006 (SEQ ID NO:6). pLIB_P was digested using the restriction endonuclease Bsal and the DNA was purified with the ..QIAquick PCR Purification Kit" (Qiagen GmbH, Hilden, Germany).
- the cloning plasmid pEX-A258_AGAT-Mp was digested using the restriction endonuclease Bsal and the DNA was purified with the ..QIAquick PCR Purification Kit" (Qiagen GmbH, Hilden, Germany).
- Example 2 Cloning of the expression plasmid pLIB_cycA_AGAT-Mp coding for CycA (NCglO453) from Corynebacterium glutamicum and the L-arginine:glycine amidinotransferase (AGAT, EC 2.1.4.1) from Moorena producens
- the expression plasmid pLIB_cycA_AGAT-Mp contains the cycA gene (NCglO453) from Corynebacterium glutamicum postitioned upstream of the AGAT-Mp gene and its promoter.
- a PCR was conducted using the primers cycA_f_Notl (Seq ID NO:7) and cycA_r_Notl (Seq ID NO:8) and genomic DNA of Corynebacterium glutamicum ATCC13032 as a template.
- the resulting PCR product contained the cycA gene (NCglO453) plus 72 bp sequence upstream of the ata start codon. It was purified with the tediousQIAquick PCR Purification Kit“ (Qiagen GmbH, Hilden, Germany).
- Plasmid pLIB_P_AGAT-Mp was digested using the restriction endonuclease Notl and the DNA was purified with the meticulousQIAquick PCR Purification Kit“ (Qiagen GmbH, Hilden, Germany).
- Notl-digested pLIB_P_AGAT-Mp was joined with the cycA containing PCR product and the matching sequence ends were assembled using the “NEBuilder HiFi DNA Assembly Cloning Kit” (New England BioLabs Inc., Ipswich, USA, Cat. No. E5520).
- the product was transformed into diligentNEB Stable Competent E. coli (High Efficiency)" (New England Biolabs, Ipswich, USA) and cells were grown on LB agar containing 25 mg/l kanamycin. Proper plasmid clones were identified by restriction digestion and DNA sequencing. The resulting plasmid was named pLIB_cycA_AGAT-Mp.
- the gene argR coding for the central repressor protein ArgR controlling the L-arginine biosynthetic pathway was inactivated.
- the plasmid pK18mobsacB_DargR was constructed as follows. Plasmid pK18mobsacB (Schafer, 1994) was cut using Xbal and the linearized vector DNA (5721 bps) was purified using theticianQIAquick Gel Extraction Kit" (Qiagen GmbH, Hilden, Germany).
- the PCR products were purified using theticianQIAquick PCR Purification Kit" (Qiagen GmbH, Hilden, Germany).
- the resulting deletion vector was named pK18mobsacB_DargR. It was verified by restriction enzyme digestion and DNA sequencing.
- pK18mobsacB_DargR was transformed into Corynebacterium glutamicum ATCC13032 (Kinoshita et al., J. Gen. Appl. Microbiol. 1957; 3(3): 193-205) by electroporation. Chromosomal integration (resulting from a first recombination event) was selected by plating on BHI agar supplemented with 134 g/l sorbitol, 2.5 g/l yeast extract and 25 mg/l kanamycin. The agar plates were incubated for 48 h at 33°C.
- Strain ATCC13032_DargR was transformed by electroporation with the expression plasmids pLIB_P_AGAT-Mp and pLIB_cycA_AGAT-Mp. Plasmid containing cells were selected with 25 mg/l kanamycin. The resulting plasmid containing strains are shown in Table 6.
- Table 6 Plasmid containing derivatives of C. glutamicum ATCC13032
- Example 5 Impact of overexpression of cycA on GAA production
- strains ATCC13032_DargR/pLIB_P_AGAT-Mp and ATCC13032_DargR/pLIB_cycA_AGAT-Mp were cultivated in the Wouter Duetz system in production medium without glycine addition and the resulting GAA titers were determined as described above.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
The present invention concerns a microorganism comprising at least one gene coding for a protein having the function of a L-arginine:glycine amidinotransferase and having an increased activity of a rt protein belonging to the Amino Acid-Polyamine-Organocation Superfamily (TC 2.A.3) and to a method for the fermentative production of guanidino acetic acid (GAA) as well as to a method for the fermentative production of creatine using such microorganism.
Description
Improved biotechnological process to produce guanidinoacetic acid (GAA) by targeted introduction or by increasing the activity of a transmembrane transport protein belonging to the Amino Acid-Polyamine-Organocation Superfamily
Guanidino acetic acid (GAA) is a colorless crystalline organic compound used as animal feed additive (e.g. W02005120246 A1 and US2011257075 A1). GAA is a natural precursor of creatine (e.g. Humm et al., Biochem. J. (1997) 322, 771-776). Therefore, the supplementation of GAA allows for an optimal supply of creatine in the organism.
The present invention pertains to a microorganism transformed to be capable of producing guanidinoacetic acid (GAA) and to a method for the fermentative production of GAA using such microorganism. The present invention also relates to a method for the fermentative production of creatine.
In biological systems GAA and ornithine are formed from arginine and glycine as starting materials by the catalytic action of an L-arginine:glycine-amidinotransferase (AGAT; EC 2.1 .4.1). This reaction is also the first step in creatine biosynthesis.
Arginine Glycine Ornithine Guanidinoacetic acid (GAA)
Guthmiller et al. (J Biol Chem. 1994 Jul 1 ;269(26):17556-60) have characterized a rat kidney AGAT by cloning and heterologously expressing the enzyme in Escherichia coli (E. coli). Muenchhoff et al. (FEBS Journal 277 (2010) 3844-3860) report the first characterization of an AGAT from a prokaryote also by cloning and heterologously expressing the enzyme in E. coli.
Fan Wenchao discloses a method for the production of creatine by fermentation of non-pathogenic microorganisms, such as Corynebacterium glutamicum (CN106065411 A). The microorganism has the following biotransformation functions: glucose conversion to L-glutamic acid; conversion of L- glutamic acid to N-acetyl-L-glutamic acid; conversion of N-acetyl-L-glutamic acid to N-acetyl-L- glutamic acid semialdehyde; conversion of N-acetyl-L-glutamic acid semialdehyde to N- acetyl-L- ornithine; conversion of N-acetyl-L-ornithine to L-ornithine; conversion of L-ornithine to L-citru Hine; conversion of L-citrulline to arginino-succinic acid; conversion of arginino-succinic acid to L- arginine; conversion of L-arginine to guanidinoacetic acid; and, finally, conversion of guanidinoacetic acid to creatine. Fan Wenchao proposes, that the microorganism overexpresses
one or more enzymes selected from the group consisting of N-acetylglutamate-synthase, N- acetylornithine-6-aminotransferase, N-acetylornithinase, ornithine-carbamoyl transferase, argininosuccinate synthetase, glycine amidino-transferase (EC: 2.1. 4.1), and guanidinoacetate N- methyltransferase (EC: 2.1 .1 .2). The microorganism overexpresses preferably glycine aminotransferase (L-arginine:glycine amidinotransferase) and guanidinoacetate N- methyltransferase.
A microorganism capable of producing guanidinoacetic acid (GAA) was published by Zhang et al. (ACS Synth. Biol. 2020, 9, 2066-275). They designed a reconstituted the ornithine cycle in E. coli by introducing a heterologous AGAT from different species (e.g., Homo sapiens, Cylindrospermopsis raciborskii, Moorea producens) and by introducing a citrulline synthesis module (e.g. ovexpression of argF and argl) and an arginine synthesis module (e.g. overexpression of argG, argH introduction of aspA) into E. coli.
Schneider and Jankowitsch (WO2021122400 A1) propose a method to produce GAA using a microorganism having a gene coding for a protein having the function of an L-arginine:glycine amidinotransferase (AGAT) and an increased carbamoyl phosphate synthase. The carbamoyl phosphate is an important precursor for the biosynthesis of GAA but also for L-arginine and other compounds.
To increase the production of GAA using a microorganism an intracellular high amount of the starting materials arginine and/or glycine are necessary. At the same time the byproduct of the AGAT reaction, L-ornithine, has to be recycled to L-arginine efficiently in order to prevent loss of carbon and energy.
Several approaches for increasing the production of one of the starting materials in GAA synthesis, i.e. L-arginine, in microorganisms are also known from literature. An overview for the metabolic engineering of Corynebacterium glutamicum (C. glutamicum) for L-arginine production is provided by Park et al. (NATURE COMMUNICATIONS | DOI: 10.1038/ncomms5618). Yim et al. (J Ind Microbiol Biotechnol (2011) 38:1911-1920) could show that inactivation of the argR, gene coding for the central repressor protein ArgR controlling the L-arginine biosynthetic pathway, by disrupting the chromosomal argR gene in C. glutamicum leads to an improved arginine-producing strain.
Ginesy et al. (Microbial Cell Factories (2015) 14:29) report the successful engineering of E. coli for enhanced arginine production. Among other, they proposed the deletion of the argR repressor gene.
On the other hand, there is also a need of an increased intracellular glycine concentration in order to increase the production of GAA. This is achieved by the internal synthesis of glycine.
Alternatively, glycine can be added to the medium and membrane transport proteins facilitate the uptake.
CycA from E. coli has been characterized as a secondary, H+ dependent uptake transporter for D- alanine, D-serine, glycine, L-alanine, D-cycloserine (Robbins73, Cosloy73) and beta-alanine (Schneider et al., Appl Microbiol Biotechnol. 2004 Oct;65(5):576-82. doi: 10.1007/s00253-004- 1636-0. Epub 2004 Jun 24. PMID: 15221223). Also, Pulvermacher et al. (Microbiology (2009), 155, 106-114; DOI 10.1099/mic.0.023598-0) report that in Escherichia coli, the cycA gene encodes a permease for the transport of D-alanine, D-serine and glycine into the cell. Hook et al. (Microorganisms. 2022 Mar 17;10(3):647. doi: 10.3390/microorganismsl 0030647. PMID: 35336222) found that a-aminobutyrate, norvaline and L-valine are also substrates for CycA and overexpression of cycA improved L-isoleucine production by reducing the formation of unwanted by-products.
A BLAST search of the CycA protein from C. glutamicum ATCC13032 (SEQ ID NO:4) against Escherichia coli (E. coli) MG1655 proteins revealed, that CycA of C. glutamicum is 66% identical to CycA (= b4208) of E. coli.
The cycA gene (=NCglO453 = cg0555 = Cgl0470 = CGL_RS02385 = dagA SEQ ID NO:3) from C. glutamicum likely codes for a transmembrane transport protein belonging to the “Amino Acid- Polyamine-Organocation (APC) Superfamily (TC 2.A.3)” (Saier et al., Nucleic Acids Res. 2021 Jan 8;49(D1):D461-D467. doi: 10.1093/nar/gkaa1004) of secondary transporters. In the genome sequence of C. glutamicum strain ATCC13032 the cycA product is annotated as a D-serine/D- alanine/glycine transporter (Genbank accession NC_003450, locus_tag=" CGL_RS02385”; see also Kalinowski et al. 2003, J Biotechnol 104:5-25. 10.1016/S0168-1656(03)00154-8). However, the CycA protein has not been biochemically characterized yet and accordingly, its function in C. glutamicum is unknown.
The problem underlying the present inventions is to provide a microorganism transformed to be capable for producing guanidinoacetic acid (GAA) in higher amounts and a method for producing GAA using such microorganism.
The problem is solved by a microorganism comprising at least one heterologous gene coding for a protein having the function of a L-arginine:glycine amidinotransferase (AGAT, e.g. EC2.1.4.1) and having an overexpressed gene coding for a transmembrane transport protein with an amino acid sequence having at least 50 % identity to the sequence according to SEQ ID NO: 4. The amino acid sequence of the transmembrane transport protein may be at least 50 %, 66 %, 70 %, 80 % or 90 % identical to the sequence according to SEQ ID NO: 4. Preferably, the amino acid sequence of the transmembrane transport protein is at least 66 % identical, more preferably identical to the sequence according to SEQ ID NO: 4.
SEQ ID NO:3 shows the nucleotide sequence of the respective cycA gene. SEQ ID NO:4 is the amino acid sequence of the CycA protein of C. glutamicum.
The CycA protein of C. glutamicum is a transmembrane transport protein belonging to the Amino Acid-Polyamine-Organocation Superfamily (TC 2. A.3) of transporters (Saier MH, Reddy VS, Moreno-Hagelsieb G, Hendargo KJ, Zhang Y, Iddamsetty V, Lam KJK, Tian N, Russum S, Wang J, Medrano-Soto A. “The Transporter Classification Database (TCDB): 2021 update.” Nucleic Acids Res. 2021 Jan 8;49(D1):D461-D467. doi: 10.1093/nar/gkaa1004).
A microorganism in the context of the present invention is an organism of microscopic size, which may exist in its single-celled form or as a colony of cells. Microorganisms include most unicellular organisms from all three domains of life. The domains Archaea and Bacteria contain microorganisms only. Among the third domain Eukaryota unicellular organism like yeasts, protists and protozoans belong to the group of microorganisms. Multicellular organisms or parts of them, like cell cultures, in particular cultures of animal cells, e.g. of human cells, are not considered as microorganism in the context of the present invention. Animal cells, e.g. human cells, are explicitly excluded from the definition of microorganisms in the context of the present invention.
The microorganism according to the present invention is capable to produce GAA in higher amounts without the addition of glycine to the production medium
A heterologous gene means that the gene has been inserted into a host organism which does not naturally have this gene. Insertion of the heterologous gene in the host is performed by recombinant DNA technology. Microorganisms that have undergone recombinant DNA technology are called transgenic, genetically modified or recombinant. A heterologous protein means a protein that is not naturally occurring in the microorganism. A homologous or endogenous gene means that the gene including its function as such or the nucleotide sequence of the gene is naturally occurring in the microorganism or is “native” in the microorganism. A homologous or a native protein means a protein that is naturally occurring in the microorganism.
In the microorganism according to the present invention the activity of the protein having the function of an L-arginine:glycine amidinotransferase (AGAT) is preferably increased compared to the respective activity in the wildtype organism. Preferably, the AGAT activity is increased by overexpression of the gene coding for the protein having the function of an L-arginine:glycine amidinotransferase.
In the microorganism according to the present invention the protein having the function of an L- arginine:glycine amidinotransferase (AGAT) comprises an amino acid sequence which is at least 80 % homologous to the amino acid sequence according to SEQ ID NO:2.
Overexpression of a gene is generally achieved by increasing the copy number of the gene and/or by functionally linking the gene with a strong promoter and/or by enhancing the ribosomal binding
site and/or by codon usage optimization of the start codon or of the whole gene and/or by modifying activities of proteins modulating gene expression or a combination comprising a selection of all methods mentioned above.
A promoter is a DNA sequence consisting of about 40 to 50 base pairs and which constitutes the binding site for an RNA polymerase holoenzyme and the transcriptional start point, whereby the strength of expression of the controlled polynucleotide or gene can be influenced. Generally, it is possible to achieve an overexpression or an increase in the expression of genes in bacteria by selecting strong promoters, for example by replacing the original promoter with strong, native (originally assigned to other genes) promoters or by modifying certain regions of a given, native promoter (for example its so-called -10 and -35 regions) towards a consensus sequence, e.g. as taught by M. Patek et al. (Microbial Biotechnology 6 (2013), 103-117) for C. glutamicum. An example for a “strong” promoter is the superoxide dismutase (sod) promoter (“Psod”; Z. Wang et al., Eng. Life Sci. 2015, 15, 73-82). A “functional linkage” is understood to mean the sequential arrangement of a promoter with a gene, which leads to a transcription of the gene.
In the present context, the extent to which protein sequences are related is expressed as identity meaning more specifically, how much of the sequence is identical according to the results of a blast search given as percentage (see https://www.ncbi.nlm.nih.gov/books/NBK62051/ for definition).
The microorganism according to the present invention may have an increased ability to produce L- arginine from L-ornithine compared with the ability of the wildtype microorganism.
In the context of the present invention, a microorganism having an increased ability to produce L- arginine means a microorganism producing L-arginine in excess of its own need. Examples for such L-arginine producing bacteria are e.g. C. glutamicum ATCC 21831 orthose disclosed by Park et al. (NATURE COMMUNICATIONS | DOI: 10.1038/ncomms5618) or by Ginesy et al. (Microbial Cell Factories (2015) 14:29). In contrast to formerly described bacteria having an increased ability to produce L-arginine, L-arginine excretion is not necessary in strains for GAA production since arginine is utilized inside the cell in the framework of the present invention for GAA production.
In a further embodiment the microorganism according to the present invention the expression of an argR gene coding for the arginine responsive repressor protein ArgR is attenuated compared to the expression of the argR gene in the wildtype microorganism. Alternatively, the argR gene is deleted.
The microorganism of the present invention may belong to the genus Corynebacterium, to the genus Bacillus (Yan, K., et al. (2022). "Biosynthesis of Guanidinoacetate by Bacillus subtilis Whole- Cell Catalysis." Fermentation 8(3):116), to the genus Enterobacteriaceae or to the genus Pseudomonas.
In a particular embodiment of the present invention the microorganism is Corynebacterium glutamicum (C. glutamicum) or Escherichia coli (E. coli).
The present invention further concerns a method for the fermentative production of guanidino acetic acid (GAA), comprising the steps of cultivating the microorganism according to the present invention in a medium, and accumulating GAA in the medium to form a GAA containing fermentation broth.
The method according to the present invention may be further characterized in that no glycine is added to the medium.
Preferably, the method further comprises isolating GAA from the GAA containing fermentation broth.
In a particular embodiment the microorganism of the present invention further comprises a gene coding for an enzyme having the activity of a guanidinoacetate N-methyltransferase. The gene coding for an enzyme having the activity of a guanidinoacetate N-methyltransferase may be overexpressed.
The present invention also concerns a method for the fermentative production of creatine, comprising the steps of a) cultivating the microorganism according to the present invention further comprising a gene coding for an enzyme having the activity of a guanidinoacetate N- methyltransferase in a suitable medium under suitable conditions, and b) accumulating creatine in the medium to form a creatine containing fermentation broth.
Preferably, the method further comprises isolating creatine from the creatine containing fermentation broth. Creatine may be extracted from fermentation broth by isoelectric point method and I or ion exchange method. Alternatively, creatine can be further purified by a method of recrystallization in water.
Brief description of the sequences
SEQ ID NO:1 : Open reading frame coding for a L-arginine:glycine amidinotransferase (AGAT_Mp, EC 2.1 .4.1 ; locus_tag BJP34_00300) of Moorena producens.
SEQ ID NO:2: The derived AGAT_Mp amino acid sequence (Genbank accession Number WP_070390602)
SEQ ID NO:3: Open reading frame NCglO453 (=cycA) of Corynebacterium glutamicum ATCC13032 (NCBI Reference Sequence: NC_003450.3)
SEQ ID NO:4: The derived amino acid sequence of NCglO453 (=cycA) (NCBI Reference Sequence: WP_231838291 .1)
SEQ ID NO:5: AGAT-Mp insert ordered for gene synthesis
SEQ ID NO:6: E. coli-C. glutamicum shuttle plasmid pLIB_P
SEQ ID NO:7: PCR primer cycA_f_Notl
SEQ ID NO:8: PCR primer cycA_r_Notl
SEQ ID NO:9: PCR primer DargRJf
SEQ ID NQ:10: PCR primer DargRJr
SEQ ID NO:11 : PCR primer DargR_rf
SEQ ID NO:12: PCR primer DargR_rr
A) MATERIALS and METHODS
Chemicals
Kanamycin solution from Streptomyces kanamyceticus was purchased from Sigma Aldrich (St. Louis, USA, Cat. no. K0254). If not stated otherwise, all other chemicals were purchased analytically pure from Merck (Darmstadt, Germany), Sigma Aldrich (St. Louis, USA) or Carl-Roth (Karlsruhe, Germany).
Cultivation for cell proliferation
If not stated otherwise, cultivation I incubation procedures were performed as follows herewith: a. LB broth (MILLER) from Merck (Darmstadt, Germany; Cat. no. 110285) was used to cultivate E. coli strains in liquid medium. The liquid cultures (10 ml liquid medium per 100 ml Erlenmeyer flask with 3 baffles) were incubated in the Infors HT Multitron standard incubator shaker from Infors GmbH (Bottmingen, Switzerland) at 30°C and 200 rpm. b. LB agar (MILLER) from Merck (Darmstadt, Germany, Cat. no. 110283) was used for cultivation of E. coli strains on agar plates. The agar plates were incubated at 30°C in an INCU- Line® mini incubator from VWR (Radnor, USA). c. Brain heart infusion broth (BHI) from Merck (Darmstadt, Germany, Cat. no. 110493) was used to cultivate C. glutamicum strains in liquid medium. The liquid cultures (10 ml liquid medium per 100 ml Erlenmeyer flask with 3 baffles) were incubated in the Infors HT Multitron standard incubator shaker from Infors GmbH (Bottmingen, Switzerland) at 30°C and 200 rpm. d. Brain heart agar (BHI-agar) from Merck (Darmstadt, Germany, Cat. no. 113825) was used for cultivation of C. glutamicum strains on agar plates. The agar plates were incubated at 30°C in an incubator from Heraeus Instruments with Kelvitron® temperature controller (Hanau, Germany). e. For cultivating C. glutamicum after electroporation, BHI-agar (Merck, Darmstadt, Germany, Cat. no. 113825) was supplemented with 134 g/l sorbitol (Carl Roth GmbH + Co. KG, Karlsruhe, Germany), 2.5 g/l yeast extract (Oxoid/ThermoFisher Scientific, Waltham, USA, Cat. no. LP0021)
and 25 mg/l kanamycin. The agar plates were incubated at 30°C in an incubator from Heraeus Instruments with Kelvitron® temperature controller (Hanau, Germany).
Determining optical density of bacterial suspensions a. The optical density of bacterial suspensions in shake flask cultures was determined at 600 nm (OD600) using the Bio-Photometer from Eppendorf AG (Hamburg, Germany). b. The optical density of bacterial suspensions produced in the Wouter Duetz (WDS) micro fermentation system (24-Well Plates) was determined at 660 nm (OD660) with the GENios™ plate reader from Tecan Group AG (Mannedorf, Switzerland).
Centrifugation a. Bacterial suspensions with a maximum volume of 2 ml were centrifuged in 1 .5 ml or 2 ml reaction tubes (e.g. Eppendorf Tubes® 381 OX) using an Eppendorf 5417 R benchtop centrifuge (5 min. at 13.000 rpm). b. Bacterial suspensions with a maximum volume of 50 ml were centrifuged in 15 ml or 50 ml centrifuge tubes (e.g. FalconTM 50 ml Conical Centrifuge Tubes) using an Eppendorf 5810 R benchtop centrifuge for 10 min. at 4.000 rpm.
DNA isolation
Plasmid DNA was isolated from E. coli cells using the QIAprep Spin Miniprep Kit from Qiagen (Hilden, Germany, Cat. No. 27106) according to the instructions of the manufacturer.
Polymerase chain reaction (PCR)
PCR with a proof reading (high fidelity) polymerase was used to amplify a desired segment of DNA for sequencing or DNA assembly. Non-proof-reading polymerase Kits were used for determining the presence or absence of a desired DNA fragment directly from E. coli or C. glutamicum colonies. a. The Phusion® High-Fidelity DNA Polymerase Kit (Phusion Kit) from New England BioLabs Inc. (Ipswich, USA, Cat. No. M0530) was used for template-correct amplification of selected DNA regions according to the instructions of the manufacturer (see Table 1).
Table 1 : Thermocycling conditions for PCR with Phusion® High-Fidelity DNA Polymerase Kit from New England BioLabs Inc. b. Taq PCR Core Kit (Taq Kit) from Qiagen (Hilden, Germany, Cat. No.201203) was used to amplify a desired segment of DNA to confirm its presence. The kit was used according to the instructions of the manufacturer (see Table 2).
Table 2: Thermocycling conditions for PCR with Taq PCR Core Kit (Taq Kit) from Qiagen. c. SapphireAmp® Fast PCR Master Mix (Sapphire Mix) from Takara Bio Inc (Takara Bio Europe S.A.S., Saint-Germain-en-Laye, France, Cat. No. RR350A/B) was used as an alternative to confirm the presence of a desired segment of DNA in cells taken from E. coli or C. glutamicum colonies according to the instructions of the manufacturer (see Table 3).
Table 3: Thermocycling conditions for PCR with SapphireAmp® Fast PCR Master Mix (Sapphire Mix) from Takara Bio Inc. d. All oligonucleotide primers were synthesized by Eurofins Genomics GmbH (Ebersberg, Germany). e. As PCR template either a suitably diluted solution of isolated plasmid DNA or of total DNA isolated from a liquid culture or the total DNA contained in a bacterial colony (colony PCR) was used. For said colony PCR the template was prepared by taking cell material with a sterile toothpick from a colony on an agar plate and placing the cell material directly into the PCR reaction tube. The cell material was heated for 10 sec. with 800 W in a microwave oven type Mikrowave & Grill from SEVERIN Elektrogerate GmbH (Sundern, Germany) and then the PCR reagents were added to the template in the PCR reaction tube. f. All PCR reactions were carried out in PCR cyclers type Mastercycler or Mastercycler nexus gradient from Eppendorf AG (Hamburg, Germany).
Restriction enzyme digestion of DNA
For restriction enzyme digestions either „FastDigest restriction endonucleases (FD)“ (ThermoFisher Scientific, Waltham, USA) or restriction endonucleases from New England BioLabs Inc. (Ipswich, USA) were used. The reactions were carried out according to the instructions of the manufacturer’s manual.
Determining the sizes of DNA fragments a. The sizes of small DNA fragments (<1000 bps) were usually determined by automatic capillary electrophoresis using the QIAxcel from Qiagen (Hilden, Germany).
b. If DNA fragments needed to be isolated or if the DNA fragments were >1000 bps DNA was separated by TAE agarose gel electrophoresis and stained with GelRed® Nucleic Acid Gel Stain (Biotium, Inc., Fremont, Canada). Stained DNA was visualized at 302 nm.
Purification of PCR amplificates and restriction fragments
PCR amplificates and restriction fragments were cleaned up using the QIAquick PCR Purification Kit from Qiagen (Hilden, Germany; Cat. No. 28106), according to the manufacturer’s instructions. DNA was eluted with 30 pl 10 mM TrisTICI (pH 8.5).
Determining DNA concentration
DNA concentration was measured using the NanoDrop Spectrophotometer ND-1000 from PEQLAB Biotechnologie GmbH, since 2015 VWR brand (Erlangen, Germany).
Assembly cloning
Plasmid vectors were assembled using the “NEBuilder HiFi DNA Assembly Cloning Kit” purchased from New England BioLabs Inc. (Ipswich, USA, Cat. No. E5520). The reaction mix, containing the linear vector and at least one DNA insert, was incubated at 50°C for 60 min. 0.5 pl of Assembly mixture was used for each transformation experiment.
Chemical transformation of E. coli
For plasmid cloning, chemically competent “NEB® Stable Competent E. coli (High Efficiency)" (New England BioLabs Inc., Ipswich, USA, Cat. No. C3040) were transformed according to the manufacturer's protocol. Successfully transformed cells were selected on LB agar supplemented with 25 mg/l kanamycin.
Transformation of C. glutamicum
Transformation of C. glutamicum with plasmid-DNA was conducted via electroporation using a „Gene Pulser Xcell" (Bio-Rad Laboratories GmbH, Feldkirchen, Germany) as described by Ruan et al. (2015). Electroporation was performed in 1 mm electroporation cuvettes (Bio-Rad Laboratories GmbH, Feldkirchen, Germany) at 1 .8 kV and a fixed time constant set to 5 ms. Transformed cells were selected on BHI-agar containing 134 g/l sorbitol, 2.5 g/l Yeast Extract and 25 mg/l kanamycin.
C. glutamicum strains
Corynebacterium glutamicum ATCC13032 (DSM 20300, Kinoshita S, Udaka S, Shimono M., J. Gen. Appl. Microbiol. 1957; 3(3): 193-205), the C. glutamicum m\d type strain, is commercially available at the American Type Culture Collection (ATCC) or at the DSMZ-German Collection of Microorganisms and Cell Cultures GmbH.
Determining nucleotide sequences
Nucleotide sequences of DNA molecules were determined by Eurofins Genomics GmbH (Ebersberg, Germany) by cycle sequencing, using the dideoxy chain termination method of Sanger et al. (Proceedings of the National Academy of Sciences USA 74, 5463 - 5467, 1977).
Clonemanager Professional 9 software from Scientific & Educational Software (Denver, USA) was used to visualize and evaluate the sequences as well as for in silico assembly of sequences.
Glycerol stocks of E. coli and C. glutamicum strains
For long time storage of E. coli- and C. glutamicum strains glycerol stocks were prepared. Selected E. coli clones were cultivated in 10 ml LB medium supplemented with 2 g/l glucose. Selected C. glutamicum clones were cultivated in 10 ml twofold concentrated BHI medium supplemented with 2 g/l glucose. Media for growing plasmid containing E. coli- and C. glutamicum strains were supplemented with 25 mg/l kanamycin. The medium was contained in 100 ml Erlenmeyer flasks with 3 baffles. It was inoculated with a loop of cells taken from a colony. The culture was then incubated for 18 h at 30°C and 200 rpm. After said incubation period 1.2 ml 85 % (v/v) sterile glycerol were added to the culture. The obtained glycerol containing cell suspension was then aliquoted in 2 ml portions and stored at -80°C.
GAA production in small-scale cultivations
The millilitre-scale cultivation system according to Duetz (2007) was used to assess the GAA- production of the strains. For this purpose, 24-deepwell microplates (24 well WDS plates) from EnzyScreen BV (Heemstede, Netherlands, Cat. no. CR1424) filled with 2.5 ml medium per well were used.
Precultures of the strains were done in 10 ml seed medium (SM). The medium was contained in a 100 ml Erlenmeyer flask with 3 baffles. It was inoculated with 100 pl of a glycerol stock culture and the culture was incubated for 24 h at 30°C and 200 rpm. The composition of the seed medium (SM) is shown in Table 4.
Table 4: Seed medium (SM)
After said incubation period the optical densities OD600 of the precultures were determined. The volume, needed to inoculate 2.5 ml of production medium (PM) to an OD600 of 0.1 , was sampled from the preculture, centrifuged (1 min at 8000 g) and the supernatant was discarded. Cells were then resuspended in 100 pl of production medium.
The main cultures were started by inoculating the 2.4 ml production medium (PM) containing wells of the 24 Well WDS-Plate with each 100 pl of the resuspended cells from the precultures. The composition of the production medium (PM) is shown in Table 5.
Table 5: Production medium (PM)
The main cultures were incubated for 72 h at 30 °C and 225 rpm in an Infors HT Multitron standard incubator shaker from Infors GmbH (Bottmingen, Switzerland) until complete consumption of glucose. The glucose concentration in the suspension was analyzed with the blood glucose-meter OneTouch Vita® from LifeScan (Johnson & Johnson Medical GmbH, Neuss, Germany).
After cultivation the culture suspensions were transferred to a deep well microplate. A part of the culture suspension was suitably diluted to measure the GD600. Another part of the culture was centrifuged and the concentration of GAA in the supernatant was analyzed as described below.
Quantification of GAA
Samples were analyzed with an analyzing system from Agilent, consisting of a HPLC “Infinity 1260” coupled with a mass analyzer “Triple Quad 6420” (Agilent Technologies Inc., Santa Clara, USA). Chromatographic separation was done on the Atlantis HILIC Silica column, 4,6X250mm, 5pm (Waters Corporation, Milford, USA) at 35°C. Mobile phase A was water with 10mM ammonium formate and 0.2% formic acid. Mobile phase B was a mixture of 90% acetonitrile and 10 % water, 10 mM ammonium formate were added to the mixture. The HPLC system was started with 100 % B, followed by a linear gradient for 22 min and a constant flow rate of 0,6 mL/min to 66 % B. The mass analyzer was operated in the ESI positive ionization mode. For detection of GAA the m/z values were monitored by using an MRM fragmentation [M+H] + 118 - 76. The limit of quantification (LOQ) for GAA was fixed to 7 ppm.
B) EXPERIMENTAL RESULTS
Example 1 : Cloning of the gene AGAT-Mp coding for an L-arginine:glycine amidinotransferase (AGAT, EC 2.1 .4.1) from Moorena producens
Moorena producens is a filamentous cyanobacterium. The genome of the Moorena producens strain PAL-8-15-08-1 was published by Leao et al. (Leao T, Castelao G, Korobeynikov A, Monroe EA, Podell S, Glukhov E, Allen EE, Gerwick WH, Gerwick L, Proc Natl Acad Sci U S A. 2017 Mar 21 ;114(12):3198-3203. doi: 10.1073/pnas.16185561 14; Genbank accession Number CP017599.1).
It contains an open reading frame coding for a L-arginine:glycine amidinotransferase (AGAT, EC 2.1.4.1 ; locus_tag BJP34_00300 shown in SEQ ID NO:1). SEQ ID NO:2 shows the derived amino acid sequence (Genbank accession Number WP_070390602).
Using the software tool ..Optimizer" (http://genomes.urv.es/OPTIMIZER/) the amino acid sequence was translated back into a DNA sequence optimized for the codon usage of C. glutamicum. The 5’- end of the optimized gene was expanded with a Bsal restriction site, a 5’-UTR sequence for assembly cloning and a ribosomal binding site. At the 3’-end a second stop-codon, a sequence for assembly cloning and a Bsal-site was added. The resulting DNA sequence was named AGAT-Mp- insert (SEQ ID NO:5) was ordered for gene synthesis from Eurofins Genomics GmbH (Ebersberg, Germany) and it was delivered as part of a cloning plasmid with an ampicillin resistance gene (designated as pEX-A258_AGAT-Mp).
The E. coli-C. glutamicum shuttle plasmid pLIB_P consists of the replication origin from pBL1 (for C. glutamicum), the pSC101 replication origin (for E. coli) and a kanamycin resistance gene. Following a unique Not restriction site it has a strong promoter, two inversely orientated Bsal-sites and the BioBricks Terminator BBa_B1006 (SEQ ID NO:6). pLIB_P was digested using the restriction endonuclease Bsal and the DNA was purified with the ..QIAquick PCR Purification Kit" (Qiagen GmbH, Hilden, Germany).
The cloning plasmid pEX-A258_AGAT-Mp was digested using the restriction endonuclease Bsal and the DNA was purified with the ..QIAquick PCR Purification Kit" (Qiagen GmbH, Hilden, Germany).
The DNA solutions of Bsal digested pLIB_P and pEX-A258_AGAT-Mp were joined, and matching sequence ends were assembled using the “NEBuilder HiFi DNA Assembly Cloning Kit” (New England BioLabs Inc., Ipswich, USA, Cat. No. E5520). The product was transformed into „NEB Stable Competent E. coli (High Efficiency)" (New England Biolabs, Ipswich, USA) and cells were grown on LB agar containing 25 mg/l kanamycin. Proper plasmid clones were identified by restriction digestion and DNA sequencing. The resulting plasmid was named pLIB_P_AGAT-Mp.
Example 2: Cloning of the expression plasmid pLIB_cycA_AGAT-Mp coding for CycA (NCglO453) from Corynebacterium glutamicum and the L-arginine:glycine amidinotransferase (AGAT, EC 2.1.4.1) from Moorena producens
The expression plasmid pLIB_cycA_AGAT-Mp contains the cycA gene (NCglO453) from Corynebacterium glutamicum postitioned upstream of the AGAT-Mp gene and its promoter.
A PCR was conducted using the primers cycA_f_Notl (Seq ID NO:7) and cycA_r_Notl (Seq ID NO:8) and genomic DNA of Corynebacterium glutamicum ATCC13032 as a template. The resulting PCR product contained the cycA gene (NCglO453) plus 72 bp sequence upstream of the ata start codon. It was purified with the „QIAquick PCR Purification Kit“ (Qiagen GmbH, Hilden, Germany).
The Plasmid pLIB_P_AGAT-Mp was digested using the restriction endonuclease Notl and the DNA was purified with the „QIAquick PCR Purification Kit“ (Qiagen GmbH, Hilden, Germany).
The DNA of Notl-digested pLIB_P_AGAT-Mp was joined with the cycA containing PCR product and the matching sequence ends were assembled using the “NEBuilder HiFi DNA Assembly Cloning Kit” (New England BioLabs Inc., Ipswich, USA, Cat. No. E5520).
The product was transformed into „NEB Stable Competent E. coli (High Efficiency)" (New England Biolabs, Ipswich, USA) and cells were grown on LB agar containing 25 mg/l kanamycin. Proper plasmid clones were identified by restriction digestion and DNA sequencing. The resulting plasmid was named pLIB_cycA_AGAT-Mp.
Example 3: Chromosomal deletion of the gene argR in ATCC13032
To improve intracellular L-Arginine formation and L-Arginine recycling from L-Ornithine, the gene argR coding for the central repressor protein ArgR controlling the L-arginine biosynthetic pathway was inactivated.
Therefore, the plasmid pK18mobsacB_DargR was constructed as follows. Plasmid pK18mobsacB (Schafer, 1994) was cut using Xbal and the linearized vector DNA (5721 bps) was purified using the „QIAquick Gel Extraction Kit" (Qiagen GmbH, Hilden, Germany).
For constructing the insert, two DNA fragments were created by PCR with the following pairs of primers (genomic DNA of ATCC13032 as template):
DargRJf (SEQ ID NO:9), + DargRJr (SEQ ID NQ:10)
= left homology arm (983 bps)
DargR_rf (SEQ ID NO:11), + DargR_rr (SEQ ID NO:12)
= left homology arm (984 bps)
The PCR products were purified using the „QIAquick PCR Purification Kit" (Qiagen GmbH, Hilden, Germany).
The linearized plasmid and the PCR products were then assembled using the “NEBuilder HiFi DNA
Assembly Cloning Kit” (New England BioLabs Inc., Ipswich, USA, Cat. No. E5520). The resulting
deletion vector was named pK18mobsacB_DargR. It was verified by restriction enzyme digestion and DNA sequencing.
For deleting the argR gene, pK18mobsacB_DargR was transformed into Corynebacterium glutamicum ATCC13032 (Kinoshita et al., J. Gen. Appl. Microbiol. 1957; 3(3): 193-205) by electroporation. Chromosomal integration (resulting from a first recombination event) was selected by plating on BHI agar supplemented with 134 g/l sorbitol, 2.5 g/l yeast extract and 25 mg/l kanamycin. The agar plates were incubated for 48 h at 33°C.
Individual colonies were transferred onto fresh agar plates (with 25 mg/l kanamycin) and incubated for 24 h at 33°C. Liquid cultures of these clones were cultivated for 24 h at 33°C in 10 ml BHI medium contained in 100 ml Erlenmeyer flasks with 3 baffles. To isolate clones that have encountered a second recombination event, an aliquot was taken from each liquid culture, suitably diluted and plated (typically 100 to 200 pl) on BHI agar supplemented with 10 % saccharose.
These agar plates were incubated for 48 h at 33°C. Colonies growing on the saccharose containing agar plates were then examined for kanamycin sensitivity. To do so a toothpick was used to remove cell material from the colony and to transfer it onto BHI agar containing 25 mg/l kanamycin and onto BHI agar containing 10 % saccharose. The agar plates were incubated for 60 h at 33°C. Clones that proved to be sensitive to kanamycin and resistant to saccharose were examined by PCR and DNA sequencing. The resulting strain was named ATCC13032_DargR.
Example 4: Transformation of C. glutamicum ATCC13032_DargR with the expression plasmids
Strain ATCC13032_DargR was transformed by electroporation with the expression plasmids pLIB_P_AGAT-Mp and pLIB_cycA_AGAT-Mp. Plasmid containing cells were selected with 25 mg/l kanamycin. The resulting plasmid containing strains are shown in Table 6.
Table 6: Plasmid containing derivatives of C. glutamicum ATCC13032
Example 5: Impact of overexpression of cycA on GAA production
To assess the impact of the overexpression of cycA on GAA production, strains ATCC13032_DargR/pLIB_P_AGAT-Mp and ATCC13032_DargR/pLIB_cycA_AGAT-Mp were cultivated in the Wouter Duetz system in production medium without glycine addition and the resulting GAA titers were determined as described above.
Table 7: Impact of the overexpression of cycA on GAA production
The cultivation of strain with the cycA gene containing plasmid resulted in a higher GAA titer, compared to ATCC13032/pLIB_P_AGAT-Mp (see Table 7). We conclude that the overexpression of the cycA gene improves the production of GAA.
Claims
1 . A microorganism comprising at least one heterologous gene coding for a protein having the function of a L-arginine:glycine amidinotransferase and having an overexpressed gene coding for a transmembrane transport protein with an amino acid sequence having at least 50 % identity to the sequence according to SEQ ID NO:4.
2. The microorganism of claim 1 , wherein the overexpression of the gene coding for a transmembrane transport protein is achieved by increasing the copy number of the gene and/or by functionally linking the gene with a strong promoter and/or by enhancing the ribosomal binding site and/or by codon usage optimization of the start codon or of the whole gene and/or by modifying activities of proteins modulating gene expression.
3 The microorganism of any of claims 1 to 2, wherein the transmembrane transport protein has an amino acid sequence having at least 66 % identity to the sequence according to SEQ ID NO:4.
4. The microorganism of any of claims 1 to 3, wherein the gene coding for the transmembrane transport protein is the cycA gene from Corynebacterium glutamicum.
5. The microorganism of any of the preceding claims, wherein the microorganism has an increased ability to produce L-arginine from L-ornithine compared with the ability of the wildtype microorganism.
6. The microorganism of claim 5, wherein the expression of an argR gene coding for the arginine responsive repressor protein ArgR is attenuated compared to the expression of the argR gene in the wildtype microorganism or wherein the argR gene is deleted.
7. The microorganism of any of the preceding claims, wherein the microorganism is Corynebacterium glutamicum or Escherichia coll.
8. A method for the fermentative production of guanidino acetic acid (GAA), comprising the steps of cultivating the microorganism as defined in any of the preceding claims in a medium, and accumulating GAA in the medium to form a GAA containing fermentation broth.
9. The method of claim 8, wherein no glycine is added to the medium.
10. The method of claims 8 or 9, further comprising isolating GAA from the GAA containing fermentation broth.
11. A microorganism as claimed in any of claims 1 to 7, further comprising a gene coding for an enzyme having the activity of a guanidinoacetate N-methyltransferase.
12. The microorganism of claim 11 , wherein the gene coding for an enzyme having the activity of a guanidinoacetate N-methyltransferase is overexpressed.
13. A method for the fermentative production of creatine, comprising the steps of cultivating the microorganism as defined in any of claims 11 or 12, and accumulating creatine in the medium to form a creatine containing fermentation broth.
14. The method of claim 13, further comprising isolating creatine from the creatine containing fermentation broth.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP22205239 | 2022-11-03 | ||
EP22205239.1 | 2022-11-03 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2024094483A1 true WO2024094483A1 (en) | 2024-05-10 |
Family
ID=84330098
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2023/079589 WO2024094483A1 (en) | 2022-11-03 | 2023-10-24 | Improved biotechnological process to produce guanidinoacetic acid (gaa) by targeted introduction or by increasing the activity of a transmembrane transport protein belonging to the amino acid-polyamine-organocation superfamily |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2024094483A1 (en) |
Citations (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005120246A1 (en) | 2004-06-09 | 2005-12-22 | Degussa Ag | Guanidino acetic acid used as an animal food additive |
WO2009129558A1 (en) * | 2008-04-24 | 2009-10-29 | Newsouth Innovations Pty Limited | Cyanobacteria saxitoxin gene cluster and detection of cyanotoxic organisms |
EP3085705A1 (en) * | 2015-04-22 | 2016-10-26 | Ajinomoto Co., Inc. | A method for producing l-isoleucine using a bacterium of the family enterobacteriaceae having overexpressed the cyca gene |
CN106065411A (en) | 2016-08-10 | 2016-11-02 | 洛阳华荣生物技术有限公司 | Fermentative Production creatine |
WO2020191079A1 (en) * | 2019-03-18 | 2020-09-24 | The Broad Institute, Inc. | Compositions and methods for modulating metabolic regulators of t cell pathogenicity |
CN111748506A (en) * | 2019-03-29 | 2020-10-09 | 中国科学院微生物研究所 | Engineering bacterium for producing glycocyamine and construction method and application thereof |
WO2021122400A1 (en) | 2019-12-19 | 2021-06-24 | Evonik Operations Gmbh | Method for the fermentative production of guanidinoacetic acid |
CN113481139A (en) * | 2021-07-29 | 2021-10-08 | 江南大学 | Recombinant bacillus subtilis for producing glycocyamine and construction method thereof |
WO2022008276A1 (en) * | 2020-07-09 | 2022-01-13 | Evonik Operations Gmbh | Method for the fermentative production of guanidinoacetic acid |
WO2022008280A1 (en) * | 2020-07-09 | 2022-01-13 | Evonik Operations Gmbh | Method for the fermentative production of guanidinoacetic acid |
WO2022243116A1 (en) * | 2021-05-21 | 2022-11-24 | Evonik Operations Gmbh | Improved biotechnological method for producing guanidino acetic acid (gaa) by inactivation of an amino acid exporter |
-
2023
- 2023-10-24 WO PCT/EP2023/079589 patent/WO2024094483A1/en unknown
Patent Citations (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005120246A1 (en) | 2004-06-09 | 2005-12-22 | Degussa Ag | Guanidino acetic acid used as an animal food additive |
US20110257075A1 (en) | 2004-06-09 | 2011-10-20 | Thomas Gastner | Guanidino acetic acid used as an animal food additive |
WO2009129558A1 (en) * | 2008-04-24 | 2009-10-29 | Newsouth Innovations Pty Limited | Cyanobacteria saxitoxin gene cluster and detection of cyanotoxic organisms |
EP3085705A1 (en) * | 2015-04-22 | 2016-10-26 | Ajinomoto Co., Inc. | A method for producing l-isoleucine using a bacterium of the family enterobacteriaceae having overexpressed the cyca gene |
CN106065411A (en) | 2016-08-10 | 2016-11-02 | 洛阳华荣生物技术有限公司 | Fermentative Production creatine |
WO2020191079A1 (en) * | 2019-03-18 | 2020-09-24 | The Broad Institute, Inc. | Compositions and methods for modulating metabolic regulators of t cell pathogenicity |
CN111748506A (en) * | 2019-03-29 | 2020-10-09 | 中国科学院微生物研究所 | Engineering bacterium for producing glycocyamine and construction method and application thereof |
WO2021122400A1 (en) | 2019-12-19 | 2021-06-24 | Evonik Operations Gmbh | Method for the fermentative production of guanidinoacetic acid |
WO2022008276A1 (en) * | 2020-07-09 | 2022-01-13 | Evonik Operations Gmbh | Method for the fermentative production of guanidinoacetic acid |
WO2022008280A1 (en) * | 2020-07-09 | 2022-01-13 | Evonik Operations Gmbh | Method for the fermentative production of guanidinoacetic acid |
WO2022243116A1 (en) * | 2021-05-21 | 2022-11-24 | Evonik Operations Gmbh | Improved biotechnological method for producing guanidino acetic acid (gaa) by inactivation of an amino acid exporter |
CN113481139A (en) * | 2021-07-29 | 2021-10-08 | 江南大学 | Recombinant bacillus subtilis for producing glycocyamine and construction method thereof |
Non-Patent Citations (27)
Title |
---|
"Genbank", Database accession no. WP_070390602 |
"NCBI", Database accession no. NC_003450.3 |
GENBANK , no. NC_003450 |
GINESY ET AL., MICROBIAL CELL FACTORIES, vol. 14, 2015, pages 29 |
GINESY M. ET AL: "Metabolic engineering of Escherichia coli for enhanced arginine biosynthesis", MICROBIAL CELL FACTORIES, vol. 14, 29, 7 March 2015 (2015-03-07), pages 1 - 11, XP021219510, ISSN: 1475-2859, DOI: 10.1186/S12934-015-0211-Y * |
GUTHMILLER ET AL., J BIOL CHEM., vol. 269, no. 26, 1 July 1994 (1994-07-01), pages 17556 - 60 |
HUMM ET AL., BIOCHEM. J., vol. 322, 1997, pages 771 - 776 |
KALINOWSKI ET AL., J BIOTECHNOL, vol. 104, 2003, pages 5 - 25 |
KINOSHITA SUDAKA SSHIMONO M., J. GEN. APPL. MICROBIOL., vol. 3, no. 3, 1957, pages 193 - 205 |
LEAO TCASTELAO GKOROBEYNIKOVAMONROE EAPODELL SGLUKHOV EALLEN EEGERWICK WHGERWICK L, PROC NATL ACAD SCI USA, vol. 114, no. 12, 21 March 2017 (2017-03-21), pages 3198 - 3203 |
LUBITZ D. ET AL: "Roles of export genes cgmA and lysE for the production of l-arginine and l-citrulline by Corynebacterium glutamicum", APPLIED MICROBIOLOGY AND BIOTECHNOLOGY, vol. 100, no. 19, 27 June 2016 (2016-06-27), pages 8465 - 8474, XP036053387, ISSN: 0175-7598, [retrieved on 20160627], DOI: 10.1007/S00253-016-7695-1 * |
M. PATEK ET AL., MICROBIAL BIOTECHNOLOGY, vol. 6, 2013, pages 103 - 117 |
MICROORGANISMS, vol. 10, no. 3, 17 March 2022 (2022-03-17) |
MUENCHHOFF ET AL.: "Escherichia coli (E. coli).", FEBS JOURNAL, vol. 277, 2010, pages 3844 - 3860 |
PARK ET AL., NATURE COMMUNICATIONS |
PULVERMACHER ET AL., MICROBIOLOGY, vol. 155, 2009, pages 106 - 114 |
SAIER ET AL., NUCLEIC ACIDS RES, vol. 49, no. 1, 8 January 2021 (2021-01-08), pages 461 - 467 |
SAIER MHREDDY VSMORENO-HAGELSIEB GHENDARGO KJZHANG YIDDAMSETTY VLAM KJKTIAN NRUSSUM SWANG J: "The Transporter Classification Database (TCDB): 2021 update.", NUCLEIC ACIDS RES., vol. 49, no. 1, 8 January 2021 (2021-01-08), pages 461 - 467 |
SANGER ET AL., PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES USA, vol. 74, 1977, pages 5463 - 5467 |
SCHNEIDER ET AL., APPL MICROBIOL BIOTECHNOL., vol. 65, no. 5, 24 June 2004 (2004-06-24), pages 576 - 82 |
SCHNEIDER F. ET AL: "Identification and characterization of the main beta-alanine uptake system in Escherichia coli", APPLIED MICROBIOLOGY AND BIOTECHNOLOGY, vol. 65, no. 5, 24 June 2004 (2004-06-24), Berlin/Heidelberg, pages 576 - 582, XP093119895, ISSN: 0175-7598, Retrieved from the Internet <URL:http://link.springer.com/article/10.1007/s00253-004-1636-0/fulltext.html> DOI: 10.1007/s00253-004-1636-0 * |
YAN, K. ET AL.: "Biosynthesis of Guanidinoacetate by Bacillus subtilis Whole-Cell Catalysis.", FERMENTATION, vol. 8, no. 3, 2022, pages 116, XP093001077, DOI: 10.3390/fermentation8030116 |
YIM ET AL., J IND MICROBIOL BIOTECHNOL, vol. 38, 2011, pages 1911 - 1920 |
Z. WANG ET AL., ENG. LIFE SCI., vol. 15, 2015, pages 73 - 82 |
ZHANG X. ET AL: "High-yield production of l-serine through a novel identified exporter combined with synthetic pathway in Corynebacterium glutamicum", vol. 19, 115, 29 May 2020 (2020-05-29), pages 1 - 14, XP093037954, Retrieved from the Internet <URL:https://link.springer.com/article/10.1186/s12934-020-01374-5/fulltext.html> DOI: 10.1186/s12934-020-01374-5 * |
ZHANG Y. ET AL: "Reconstitution of the Ornithine Cycle with Arginine:Glycine Amidinotransferase to Engineer Escherichia coli into an Efficient Whole-Cell Catalyst of Guanidinoacetate", ACS SYNTHETIC BIOLOGY, vol. 9, no. 8, 23 July 2020 (2020-07-23), pages 2066 - 2075, XP055762447, ISSN: 2161-5063, DOI: 10.1021/acssynbio.0c00138 * |
ZHANG, ACS SYNTH. BIOL., vol. 9, 2020, pages 2066 - 275 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2571932C2 (en) | Method of producing l-ornithine using lyse overexpressing bacteria | |
WO2021122400A1 (en) | Method for the fermentative production of guanidinoacetic acid | |
AU2021304393A1 (en) | Method for the fermentative production of guanidinoacetic acid | |
AU2608801A (en) | Increased lysine production by gene amplification | |
AU2021303704A1 (en) | Method for the fermentative production of guanidinoacetic acid | |
CN109797126B (en) | Recombinant bacterium for producing L-serine and construction method thereof | |
WO2022243116A1 (en) | Improved biotechnological method for producing guanidino acetic acid (gaa) by inactivation of an amino acid exporter | |
WO2024094483A1 (en) | Improved biotechnological process to produce guanidinoacetic acid (gaa) by targeted introduction or by increasing the activity of a transmembrane transport protein belonging to the amino acid-polyamine-organocation superfamily | |
JP4383984B2 (en) | Method for producing L-threonine | |
WO2024094481A1 (en) | Improved biotechnological process to produce guanidinoacetic acid (gaa) by targeted introduction or by increasing the activity of a transmembrane exporter protein | |
JP2023540330A (en) | Corynebacterium glutamicum mutant strain with improved L-citrulline production ability and method for producing L-citrulline using the same | |
WO2021048353A1 (en) | Coryneform bacteria with a heterologous threonine transporter and their use in the production of l-threonine | |
US11999982B2 (en) | Method for the fermentative production of guanidinoacetic acid | |
WO2023232583A1 (en) | Improved biotechnological method for producing guanidino acetic acid (gaa) by using nadh-dependent dehydrogenases | |
WO2023232584A1 (en) | Method for producing guanidino acetic acid (gaa) | |
TW202417609A (en) | Improved biotechnological method for producing guanidino acetic acid (gaa) by using a carbamate kinase | |
CN117355537A (en) | Improved biotechnological process for the production of guanidinoacetic acid (GAA) by inactivation of amino acid export proteins | |
TW202413629A (en) | Improved biotechnological method for producing guanidino acetic acid (gaa) by using nadh-dependent dehydrogenases | |
CN116536237B (en) | Modified escherichia coli and application thereof in fermentation production of L-valine | |
CN116555150B (en) | Recombinant Escherichia coli for fermentative production of L-valine | |
CN115948402A (en) | Recombinant Shewanella capable of producing 5-aminolevulinic acid and application thereof | |
CN115873852A (en) | Recombinant nucleic acid sequence, genetic engineering bacteria and method for producing 1,5-pentanediamine | |
CN115028694A (en) | Protein related to L-glutamic acid yield, and related biological material and application thereof | |
CN115873880A (en) | Recombinant nucleic acid sequence, recombinant expression vector and genetically engineered bacterium | |
CN116555152A (en) | Coli, construction method thereof and application thereof in L-valine production |